Regulatory affairs, quality assurance, and biopharma executive teams rely on U.S. Food and Drug Administration (FDA) guidance documents to understand how the agency interprets statutes, evaluates clinical endpoints, applies Good Manufacturing Practice (GMP), and enforces advertising standards. While guidance documents do not carry the binding force of federal regulation, they define the operational baseline for drug, biologic, and medical device submissions.
However, an empirical analysis of FDA’s active guidance database reveals a marked structural shift in agency output. Under the weight of post-2025 administrative transition policies, executive orders limiting sub-regulatory proliferation, and internal organizational restructuring, FDA’s pace of new guidance publication has slowed dramatically—even as the proportion of unresolved draft guidances has climbed to historic highs.
How many FDA guidance documents are there in 2026?
As of mid-2026, FDA’s active guidance database contains 2,786 total guidance records. Of these, 2,373 (85.2%) are Final Guidances, while 413 (14.8%) remain in Draft status.
================================================================================
FDA ACTIVE GUIDANCE REGISTRY SNAPSHOT (2026)
================================================================================
Total Active Guidance Records: 2,786
├── Final Guidances: 2,373 (85.2%)
└── Draft Guidances: 413 (14.8%)
By Document Category:
├── Standard Guidance Documents: 2,185 (78.4%)
├── Compliance Policy Guides (CPG): 469 (16.8%)
├── Small Entity Compliance Guides: 66 (2.4%)
└── Other (Memoranda, Letters): 66 (2.4%)
================================================================================
By document category, standard Guidance Documents represent the vast majority (2,185 records), followed by Compliance Policy Guides (CPGs) with 469 records, and Small Entity Compliance Guides with 66 records. Formal industry letters, memoranda, and information sheets account for the remainder.
| Document Type | Active Count | Share of Registry | Target Audience & Enforcement Function |
|---|---|---|---|
| Standard Guidance Document | 2,185 | 78.4% | Sets clinical trial design, CMC, and regulatory submission expectations for sponsors |
| Compliance Policy Guide (CPG) | 469 | 16.8% | Instructs FDA field inspectors and investigators on enforcement discretion and audit priorities |
| Small Entity Compliance Guide | 66 | 2.4% | Mandated statutory summaries tailored for small businesses following major rulemakings |
| Other (Letters, Memoranda, Papers) | 66 | 2.4% | Specialized policy clarifications, inter-center agreements, and administrative notices |
| Total Active Registry | 2,786 | 100.0% | Comprehensive active guidance baseline across all FDA centers |
While a repository of nearly 2,800 documents suggests a dense regulatory framework, looking solely at total volume masks a critical operational trend: the annual rate of new guidance creation is experiencing a multi-year contraction.
Is FDA guidance output really slowing down?
Yes. Annual new guidance issuance peaked in 2023 at 179 new documents. Output fell to 155 in 2024 (-13.4%), dropped further to 104 in 2025 (-32.9%), and stands at 84 documents through July 2026.
Comparing calendar year 2023 to 2025 shows a 41.9% overall decline in new guidance output across the agency.
NEW GUIDANCE ISSUANCE TREND (2022 – 2026 YTD)
--------------------------------------------------------------------------------
2022 ████████████████████████████████████ (141)
2023 █████████████████████████████████████████████ (179) [Peak Output]
2024 ███████████████████████████████████ (155)
2025 ██████████████████████ (104) [-41.9% vs 2023]
2026* ██████████████████ (84 through July)
--------------------------------------------------------------------------------
Even more telling than the headline volume drop is the inversion of the Final vs. Draft mix.
Historically, FDA finalized a substantial majority of the new guidances it issued each year. In 2022, only 19.1% of newly published guidances were Drafts. In 2023, Drafts comprised 27.9% of new issuances. By 2025, however, Draft guidances accounted for 52.9% of all newly issued documents (55 out of 104)—marking the first majority-Draft year in the modern tracking record.
Detailed Breakdown of Annual Guidance Issuances (2022–2026 YTD)
| Calendar Year | Total New Issued | Final Issued | Draft Issued | Draft Share (%) | YoY Total Volume Change |
|---|---|---|---|---|---|
| 2022 | 141 | 114 | 27 | 19.1% | Baseline Year |
| 2023 | 179 | 129 | 50 | 27.9% | +27.0% Growth |
| 2024 | 155 | 95 | 60 | 38.7% | -13.4% Decline |
| 2025 | 104 | 49 | 55 | 52.9% | -32.9% Decline |
| 2026 (YTD) | 84 | 52 | 32 | 38.1% | Partial Year Snapshot |
This Draft-heavy mix creates significant regulatory friction for biopharma sponsors. Draft guidances reflect FDA's "current thinking," but because they are technically open for public comment and subject to revision, sponsors face uncertainty over whether reviewer expectations will shift before product approval. The growing backlog of un-finalized draft guidances leaves key therapeutic and technological areas in regulatory limbo.
Which FDA center issues the most guidance?
The Center for Drug Evaluation and Research (CDER) remains the dominant producer of guidance documents, representing approximately 1,101 active records (39.5% of the total registry). The Center for Food Safety and Applied Nutrition (CFSAN/Foods) and the Center for Devices and Radiological Health (CDRH) follow with roughly 500 active records each.
ACTIVE GUIDANCES BY ISSUING CENTER (2026 SNAPSHOT)
--------------------------------------------------------------------------------
CDER (Drug Evaluation) ████████████████████████████████ (1,101)
Foods / CFSAN ███████████████ (502)
CDRH (Device Evaluation) ███████████████ (498)
CVM (Veterinary Medicine) █████████ (290)
CBER (Biologics Evaluation)█████ (168)
Other / Cross-Center █████ (168)
CTP (Tobacco Products) █ (44)
OCE (Oncology Excellence) █ (15)
--------------------------------------------------------------------------------
However, examining annual issuance rates by center illustrates that the output contraction has hit medical devices and drug development unevenly:
Center-by-Center Annual Issuance Comparison
| Issuing Center | 2022 Issued | 2023 Issued | 2024 Issued | 2025 Issued | 2-Year Output Shift (2023 → 2025) |
|---|---|---|---|---|---|
| CDER (Drug Evaluation) | 77 | 87 | 72 | 52 | -40.2% Decline |
| CDRH (Device Evaluation) | 31 | 35 | 29 | 16 | -54.3% Decline |
| CBER (Biologics Evaluation) | 6 | 9 | 11 | 12 | +33.3% Growth |
| CVM (Veterinary Medicine) | 14 | 18 | 15 | 9 | -50.0% Decline |
| Total (All Centers) | 141 | 179 | 155 | 104 | -41.9% Overall Decline |
- CDRH experienced the steepest relative decline, dropping 54.3% from 35 new guidances in 2023 to just 16 in 2025. In CDRH’s FY2025 guidance agenda, the center published only 11 of its 15 targeted "A-list" guidances and formally declined to pursue 4 planned topics. For FY2026, CDRH’s proposed agenda shrank to ~21 total items.
- CDER output contracted by 40.2%, falling from 87 new documents in 2023 to 52 in 2025. While CDER maintained generic Product-Specific Guidance (PSG) releases—such as the batch of 48 new/revised draft PSGs issued in May 2025—broad policy guidances covering clinical trial design and CMC validation slowed.
- CBER maintained modest growth, rising from 9 guidances in 2023 to 12 in 2025. This resilience reflects urgent regulatory needs in cell and gene therapy (CGT) manufacturing, viral vector potency assays, and tissue-engineered products.
This trajectory mirrors broader enforcement and oversight metrics across the agency. As detailed in our analysis of FDA Warning Letters by the numbers (2026), formal enforcement actions have similarly evolved alongside shifts in agency inspection capacity and administrative priorities.
What caused the guidance slowdown in 2025–2026?
The drop in FDA guidance production is not an accident of administrative lag; it is the direct outcome of three structural policy and organizational changes initiated in early 2025:
1. Executive Order "Ten-for-One" Regulatory Restrictions
In January 2025, the presidential administration signed executive orders establishing strict deregulation quotas, including a "ten-for-one" mandate requiring executive branch agencies to identify ten existing guidance documents or sub-regulatory rules for rescission before issuing one new major policy guidance. While sub-regulatory agency guidance is technically non-binding, federal oversight bodies classified major policy guidances under Executive Order review protocols, severely raising the internal justification bar for publishing new policy documents.
2. Administrative Issuance Freezes and Departmental Clearance
Following the leadership transition, HHS instituted a mandatory department-wide clearance process for all public guidance documents. Draft guidances that had completed technical review within CDER or CDRH were held in extended departmental review, creating a multi-month freeze during early 2025.
3. Reductions-in-Force (RIF) and Staff Reallocations
Personnel cuts across HHS and FDA directly targeted policy development divisions. A prime example occurred in April 2025, when FDA eliminated the Policy Division within the Office of Prescription Drug Promotion (OPDP). By stripping out dedicated policy-drafting personnel, the agency significantly reduced its internal throughput for advertising, promotional, and commercial compliance guidance.
--------------------------------------------------------------------------------
DRIVERS OF THE 2025-2026 GUIDANCE SLOWDOWN
--------------------------------------------------------------------------------
[Jan 2025] Executive Order "Ten-for-One" Rescission Mandate
↳ High administrative barrier to publish new policy documents
[Feb 2025] HHS Department-Wide Guidance Clearance Freeze
↳ Extended holding periods for CDER/CDRH policy drafts
[Apr 2025] Elimination of OPDP Policy Division & Policy Staff RIFs
↳ Loss of dedicated policy drafting personnel inside FDA centers
--------------------------------------------------------------------------------
As a result of these constraints, FDA center directors have pivoted toward issuing targeted, technical updates—such as product-specific bioequivalence guidelines—rather than sweeping cross-cutting policy frameworks.
Which 2025–2026 guidances matter most for drug and device sponsors?
Despite lower total volume, several high-impact guidances issued or updated in 2025 and 2026 establish essential compliance benchmarks for biopharma and medtech sponsors:
1. Product-Specific Guidances (PSGs) for Complex Generics (May 2025 Batch)
FDA released a batch of 48 new and revised draft PSGs providing bioequivalence (BE) recommendations for complex drug products. This batch included updated BE expectations for transdermal delivery systems (TDS), topical formulations, and long-acting injectables—critical inputs for ANDA applicants seeking to establish sameness.
2. FDA Human Factors Final Guidance (2026)
CDRH finalized its long-awaited guidance on human factors engineering for medical device marketing submissions. The final guidance establishes three distinct submission categories based on device risk and modification scope, providing clear criteria for when human factors validation data must be submitted in 510(k) and PMA applications. This document directly impacts sponsors navigating FDA device clearances and approvals by the numbers.
3. Artificial Intelligence and Machine Learning (AI/ML) Lifecycle Management
Following draft frameworks on Predetermined Change Control Plans (PCCP), CDRH and CDER issued joint clarifications on Good Machine Learning Practice (GMLP) and post-market algorithm monitoring. For developers of software as a medical device (SaMD), these documents set the baseline for lifecycle validation, as discussed in our overview of FDA AI/ML-enabled medical devices.
4. Decentralized Clinical Trials (DCT) and Digital Health Technologies (DHT)
CDER finalized recommendations for using digital health technologies (e.g., wearable sensors, remote patient monitoring) for data acquisition in clinical investigations. The guidance details data integrity, verification, and validation standards required when replacing traditional in-person clinical trial visits with remote telemetry.
5. Cell and Gene Therapy (CGT) Vector Quality & Potency Assays
CBER released updated guidelines on CMC expectations for adeno-associated virus (AAV) and lentiviral vector testing. The document establishes strict lot-release requirements for full-to-empty capsid ratios and potency assay matrix validation prior to initiating pivotal Phase 3 trials.
Strategic Recommendations for Regulatory & Clinical Teams
Given the contraction in official guidance output and the rising share of draft-status documents, biopharma and medtech teams should adjust their regulatory strategies:
================================================================================
REGULATORY STRATEGY MATRIX IN A GUIDANCE SLOWDOWN
================================================================================
Guidance Challenge Operational Risk Recommended Action
--------------------------------------------------------------------------------
53% Draft Guidance Share Draft policies subject to change Use Type C / Q-Sub meetings
before final product approval to lock in agency alignment
CDRH Guidance Contraction Fewer device policy updates Benchmark against recent 510(k)
(-54% drop in issuance) clearance summary documents
OPDP Division Elimination Delayed promotional review Utilize advisory submission
guidelines and enforcement rules pathways for launch campaigns
Ten-for-One EO Mandate Increased risk of sudden Audit legacy draft guidances
guidance rescissions for withdrawal vulnerabilities
================================================================================
- Do Not Wait for Final Guidance on Emerging Technologies: With 53% of new 2025 guidances stuck in draft status, waiting for a "Final" version before finalizing clinical trial protocols or CMC validation plans risks multi-year product delays. Engage FDA early via Type C meetings or Q-Submissions using current draft frameworks as the discussion baseline.
- Audit Product-Specific Guidance (PSG) Postings Quarterly: While general policy guidances have slowed, CDER continues to update PSGs for complex small molecules and peptides. Monitor quarterly PSG releases to ensure ongoing ANDA bioequivalence studies align with modified FDA testing protocols.
- Establish Strong Primary-Source Evidence: In areas where FDA guidance has been delayed or withdrawn under executive order mandates, rely directly on primary statutory text (FD&C Act, PHS Act), published FDA approval packages (SBDs), and formal meeting minutes rather than third-party summaries.
Frequently Asked Questions
Are draft guidances being finalized or withdrawn faster in 2025–2026?
No. Rather than being finalized rapidly, draft guidances are lingering longer in draft status due to review bottlenecks and policy staff reductions. In 2025, 52.9% of newly published guidances were drafts, building up a larger un-finalized backlog rather than accelerating the path to final policy.
How does the guidance slowdown compare across CDER, CDRH, and CBER?
CDRH experienced the sharpest decline (-54.3% between 2023 and 2025), dropping to just 16 new guidances in 2025. CDER dropped 40.2% over the same period (from 87 to 52). CBER was the exception, increasing output from 9 to 12 guidances to address rapid developments in cell and gene therapy manufacturing.
What is the difference between a Final and Draft guidance, and why does the mix matter?
Draft guidances represent FDA’s preliminary thinking and are published to solicit public comment; they do not bind the agency or sponsors. Final guidances reflect settled agency policy. A higher draft share increases regulatory uncertainty for sponsors, who must decide whether to build development programs around guidelines that could change prior to submission.
What is a Small Entity Compliance Guide (SECG) and why are there only 66 in the registry?
Small Entity Compliance Guides are mandated under the Small Business Regulatory Enforcement Fairness Act (SBREFA). FDA issues an SECG only after publishing a major final rule that has a significant economic impact on a substantial number of small entities. Because major rulemakings occur far less frequently than general policy guidance publications, SECGs represent a small fraction (2.4%) of the guidance registry.
Sources
- U.S. Food and Drug Administration. Guidances Search Database. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidances
- U.S. Food and Drug Administration (CDRH). CDRH Proposed Guidances for Fiscal Year 2026 (FY2026). https://www.fda.gov/medical-devices/guidance-documents-medical-devices-and-radiation-emitting-products/cdrh-proposed-guidances-fiscal-year-2026-fy2026
- Hyman, Phelps & McNamara FDA Law Blog. Where Have All the Good Guidance Gone? (October 2025). https://www.thefdalawblog.com/2025/10/where-have-all-the-good-guidance-gone
- AgencyIQ by POLITICO. The 176 guidance documents that FDA is currently working on. https://www.agencyiq.com/blog/the-176-guidance-documents-that-fda-is-currently-working-on-affecting-the-life-sciences-industry
- Morgan Lewis & Bockius LLP. Navigating FDA's Evolving Approach to Guidance Publication for Medical Products (June 2025). https://www.morganlewis.com/blogs/asprescribed/2025/06/navigating-fdas-evolving-approach-to-guidance-publication-for-medical-products
- ProPharma Group. FDA Regulatory Disruption Impacts 2026 Pharma Advertising & Promotion (2026). https://www.propharmagroup.com/thought-leadership/fda-regulatory-disruption-impacts-2026-pharma-advertising-promotion
- Therapeutic Innovation & Regulatory Science (Springer). Semantic Search of FDA Guidance Documents. (2025). https://link.springer.com/article/10.1007/s43441-025-00798-8
